(Reuters) – The U.S. Food and Drug Administration on Wednesday approved drugmaker Incyte Corp’s treatment for a type of graft-versus-host disease (GvHD).
GvHD is a systemic disorder that occurs when immune cells from transplanted tissue recognize the recipient’s body as foreign and attack its cells.
(Reporting by Sruthi Narasimha Chari in Bengaluru; Editing by Mohammed Safi Shamsi)
Comments